SML3915
Cabozantinib malate
≥98% (HPLC)
동의어(들):
BMS 907351 (S)-malate, BMS-907351 (S)-malate, BMS907351 (S)-malate, Cabozantinib (L)-malate, Cabozantinib (S)-malate, N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane1,1-dicarboxamide, (2S)-hydroxybutanedioate, N-(4-{[6,7-bis(Methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (L)-malate salt, XL 184 (S)-malate, XL-184 (S)-malate, XL184 (S)-malate
About This Item
추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
저장 조건
desiccated
색상
white to beige
solubility
DMSO: 2 mg/mL, clear
저장 온도
-10 to -25°C
SMILES string
Fc1ccc(cc1)NC(=O)C5(CC5)C(=O)Nc2ccc(cc2)Oc3c4c(ncc3)cc(c(c4)OC)OC.O[C@@H](CC(=O)O)C(=O)O
InChI
1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
생화학적/생리학적 작용
Cabozantinib (XL184; BMS‐907351) is an orally active, potent inhibitor against multiple receptor tyrosine kinases, notably VEGFR2/KDR (IC50 = 35 pM), MET (IC50 = 1.3 nM/wt, 3.8 nM/Y1248H, 11.8 nM/D1246N, 14.6 nM/K1262R), KIT, RET, AXL, TIE2, and FLT3 (IC50 = 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib inhibits MET-driven proliferation in cancer cultures (IC50 = 9.9 nM/Hs746T, 19 nM/SNU-5) and simultaneously suppressing metastasis, angiogenesis and tumor growth in vivo (3-100 mg/kg via single or daily p.o. to mice with human MDA-MB-231 xenograft, 1-60 mg/kg via single or daily p.o. to rats with C6 rat glioma).
주의사항
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2
표적 기관
Bone marrow,Kidney,Endocrine system,Gastrointestinal tract,Liver
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
가장 최신 버전 중 하나를 선택하세요:
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.